# A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

> **NCT04354480** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** RSV Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04354480
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-15
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-01-20
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354480, "A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04354480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*